Epidermal growth factor receptors (EGFR), the first of four members of the ErbB family, play essential roles in both normal physiological and cancerous conditions. EGFR is characterised by an extracellular ligand-binding domain, which when activated by the ligand leads to the receptor dimerisation; a transmembrane domain, responsible for the dimerisation; and an intracellular tyrosine kinase domain that activates the intracellular kinase domain and the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptor.

Gastric gastrointestinal stromal tumour is an extremely rare condition to occur after bariatric surgery. To the authors’ knowledge, only two cases of gastric gastrointestinal stromal tumours after Roux-en-Y gastric bypass have been reported in the medical literature, both occurring in the excluded gastric remnant. Herein, the authors report the third case of gastric gastrointestinal stromal tumour post-Roux-en-Y gastric bypass, and the first case to occur in the gastric pouch, which was managed surgically by laparoscopic resection. From here, combining the observations of clinicians treating and following up patients post-bariatric surgery in an international database will be beneficial to patients, and aid in development of surveillance guidelines.

Acute myeloid leukaemia (AML) is a rapidly progressing haematological cancer with a poor prognosis. This infographic summarises the key results from an online survey conducted in 2022 on the perceptions of AML treatments among clinicians in Europe. Haematologists and oncologists from five European countries were asked their opinions on topics such as first-line treatments, the intensity of treatment regimens, and therapies for curative intent for patients with AML.

The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population.